Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 1/20 | 0.50 |
| ▸ | MAT2A | P31153 | 1/20 | 0.43 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.40 |
| ▸ | ABL1 | P00519 | 6/20 | 0.38 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.38 |
| ▸ | MAPKAPK2 | P49137 | 2/20 | 0.37 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.36 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.36 |
| ▸ | ALPI | P09923 | 1/20 | 0.36 |
| ▸ | KDM5A | P29375 | 1/20 | 0.36 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.36 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.36 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.36 |
| ▸ | GCGR | P47871 | 2/20 | 0.35 |
| ▸ | BCR | P11274 | 1/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4714513 | 0.94 | CDC7 (0.58) | CDC7MAT2AUSP30SCN9AABL1 | |
| Trifluoroacetic Acid SCHEMBL4715188 | 0.88 | CDC7 (0.52) | CDC7MAT2AUSP30SCN9AABL1 | |
| SCHEMBL4715783 | 0.86 | CDC7 (0.53) | CDC7MAPKAPK2LRRK2 | |
| SCHEMBL4712547 | 0.86 | CDC7 (0.47) | CDC7MAT2AUSP30SCN9AMAPKAPK2 | |
| SCHEMBL14188357 | 0.83 | CDC7 (0.56) | CDC7MAPKAPK2 | |
| Trifluoroacetic Acid SCHEMBL4712543 | 0.82 | CDC7 (0.48) | CDC7ABL1MAPKAPK2BCR | |
| SCHEMBL4716236 | 0.80 | CDC7 (0.53) | CDC7ABL1MAPKAPK2BCR | |
| SCHEMBL4716543 | 0.80 | CDC7 (0.53) | CDC7ABL1MAPKAPK2 | |
| SCHEMBL14188296 | 0.80 | CDC7 (0.62) | CDC7MAT2AABL1MAPKAPK2BCR | |
| Trifluoroacetic Acid SCHEMBL4717244 | 0.79 | CDC7 (0.45) | CDC7ABL1MAPKAPK2KDM5AKDM4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080113971-A1 | PYRAZOLE COMPOUNDS AS PROTEIN KINASE INHIBITORS | HANAU CATHLEEN E | 2008-05-15 | — | — | US | disclosed |
| US-20080113971-A1 | PYRAZOLE COMPOUNDS AS PROTEIN KINASE INHIBITORS | HANAU CATHLEEN E | 2008-05-15 | — | — | US | disclosed |
| US-20080113971-A1 | PYRAZOLE COMPOUNDS AS PROTEIN KINASE INHIBITORS | HANAU CATHLEEN E | 2008-05-15 | — | — | US | disclosed |
| EP-1572682-A4 | ACYCLIC PYRAZOLE COMPOUNDS | PHARMACIA CORP (US) | 2008-01-23 | — | — | EP | disclosed |
| EP-1572682-A2 | ACYCLIC PYRAZOLE COMPOUNDS | Pharmacia Corporation (US) | 2005-09-14 | — | — | EP | disclosed |
| US-20040152739-A1 | Acyclic pyrazole compounds for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | PHARMACIA CORPORATION | 2004-08-05 | — | — | US | disclosed |
| WO-2004058176-A2 | ACYCLIC PYRAZOLE COMPOUNDS | PHARMACIA CORPORATION (US) | 2004-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080113971-A1 | PYRAZOLE COMPOUNDS AS PROTEIN KINASE INHIBITORS | MKNK2, MAPKAPK2, MAP3K2 | CDC7 487/4885MAT2A 791/4885USP30 2422/4885 |
| US-20040152739-A1 | Acyclic pyrazole compounds for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | MAPKAPK2, MAP3K2, MAP4K2 | CDC7 331/4885MAT2A 708/4885USP30 2963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.